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Some peptides containing optically active L- and D-pipecolic acid, as fragments of pipe-
colic acid-bradykinin analogues, were prepared and their physical constants were determined. 
For investigating the connections between chemical structure and biological 
activity of known peptide hormones, preparation and study of the biological 
properties of analogues containing one or several "non-proteinogenic" amino 
acids is of great importance [1]. The well-known tissue hormone bradykinin (arginyl-
prolyl-prolyl-glicyl-phenylalanyl-seryl-prolyl-phenylalanyl-arginine) with complex 
effects contains three prolines. In order to clear up the biological role of the latter, 
it seems theoretically interesting to substitute one or more prolines by "non-proteino-
genic" amino acids of only slightly different structure. 
Among the numerous possibilities, our research group used optically active 
pipecolic acid* and a-L-homoproline for the substitution of proline. 
a-L-homoproline had not been applied earlier in peptide chemistry. Publication 
of some results concerning rational synthesis of a-L-homoproline, preparation 
of several protected and active derivatives and of a-L-homoproline-bradykihin 
elaborated in our group as well as of the results of biological ^investigations is in 
course [2]. 
Numerous papers on substitution of proline by pipecolic acid can be found 
in the literature of peptide chemistry. The first report on application of L- and D-
pipecolic acid is found in connection with the synthesis of collagen models [3]. 
7-L-Pipecolic acid-oxytocin [4] and 7-L-pipecolic acid-angiotensine II [5] were 
also prepared, the latter by the method of solid phase peptide synthesis [6]. ¿-Pipe-
colic acid was applied for preparing a sequence-polypeptide [7], too. 
* The synthesis of further analogues with conventional [9] and solid phase 
peptide synthesis methods [10] followed that of the first pipecolic acid-bradykinin 
[8] only about ten years later. 
•Nomenclature and abbreviations are those accepted by IUPAC-IUB for peptide chemistry: 
Pip = pipecolic acid (piperidine-2-carboxylic acid); HPro = a-homoproline (pyrrolidine-2-acetic 
acid). Z = benzyloxycarbonyl ; BOC = /-butyloxycarbonyl; ONb = p-nitrobenzyl; OMe = methyl. 
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In order to fill up gaps in literature, special attention was paid to peptide 
chemical application of optically active pipecolic acids. Therefore the preparation 
of different protected and active derivatives of both L- and D-pipecolic acid [11, 12] 
and possibilities of their applications [13] were published in detail. 
In our preceding paper [14] we reported on preparation of some di- and tri-
peptides containing L- and D-pipecolic acids by the stepwise method. In this paper 
we describe the preparation of greater fragments, namely tetra-, penta-, hexa-, 
hepta- and octapeptides. A publication on the synthesis of pipecolic acid-bradykinin 
analogues from these fragments, on their purification and biological assays is under 
preparation [15]. 
The synthesis of each fragment described (Table I) started from the C-terminal 
tripeptides [14] and proceeded by stepwise condensation (1—6) and (9—13), acy-
lating with an active derivative of the respective protected amino acid. For hexa-
peptides (7 and 8), fragment condensation starting from tripeptides was applied. 
For preparation of tetrapeptides (3 and 4) azide coupling without isolation, for the 
penta- and hexapeptides (3—6) the N-hydroxysuccinimid esters of thé protected 
acyl components were used. Coupling of the tripeptide fragments to hexapeptides 
(7 and 8) was performed by the azide method. Acylation of heptapeptides 
(9 and 10) to octapeptides could be succesfully performed only by the dicyclohexyl-
carbodiimid method. In the latter case the active ester methods did not prove suit-
able; an exact explanation for this fact cannot be given up to now. 
Experimental 
Melting points were determined with a Kofler block, optical rotations with 
a Zeiss polarimeter. The values given are uncorrected. TLC on Kiesel G (Merck) 
was used for purity control with the following systems: 
1. «-butanol—acetic acid—water 4:1:1 
2. ethyl acetate—pyridine—acetic acid—water 60:20:6:11 
3. ethyl acetate—pyridine—acetic acid—water 30:20:6:11 
4.. ethyl acetate—pyridine—acetic acid—water 120:20:6:11 
5. chloroform—methanol 8:2 
6. chloroform—methanol—acetic acid 85:10:5 
p-Nitrobenzyl t-butyloxycarbonyl-L-seryl-D-pipecolyl-L-phenylalanyl-
-L-nitroargininate (1) 
5.34 g (7.5 mmole) protected tripeptide ester [14] was treated with slight excess 
of trifluoroacetic acid at room temperature for 1 hour. The excess acid was evaporated 
in vacuum, and the trifluoroacetate of the tripeptide ester was precipitated with ether, 
then filtered, washed with ether several times and dried in vacuum. 1.64 g (7.5 mmole) 
/-butyloxycarbonyl-L-serine hydrazide was dissolved. in 10 ml dimethylformamide 
and the solution cooled to — 15°C. 3.75 ml 6N hydrochloric acid and concentrated 
aqueous solution of 0.54 g sodium nitrite were added dropwise to the solution under 
stirring, and stirred for further 5 minutes. The trifluoroacetate of the tripeptide ester 
was dissolved similarly in 10 ml dimethylformamide, cooled to — 15°C, then 
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0.83 ml (7.5 mmole) N-methylmorpholine was added dropwise to the solution and 
stirred for 3 minutes. The azide solution was added to the latter solution and the 
reaction mixture was stirred under — 5°C for 2 hrs, then left to stand in a refrigerator 
overnight. After pouring the reaction mixture into water, the organic phase was 
extracted with ethyl acetate, the extract washed with diluted solutions of citric . 
acid and sodium hydrocarbonate, then with IN ammonium hydroxide and water. 
After drying, the extract was evaporated in vacuum and the residue crystallized. 
Methyl t-butyloxycarbonyl-L-phenylalanyl-L-seryl-L-pipecolyl-
-L-phenylalahyl-L-nitroargininate (4) 
2.41 g (4 mmole) protected tetrapeptide ester (2) was treated with slight excess 
of trifluoroacetic acid at room temperature for 1 hour. The excess acid was evaporated 
in vacuum, and the trifluoroacetate of the tetrapeptide ester precipitated with ether, 
then filtered, washed with ether and dried in vacuum. The dried product was dissolved 
in 20 ml dimethylformamide, the solution cooled to 0°C, then equivalent quantity 
of N-methylmorpholine and finally 1.45 g (4 mmole) N-hydroxysuccinimide i-butyl-
oxycarbonyl-L-phenylalaninate were added. The reaction mixture was stirred at 
the same temperature for 2hrs, then left to stand at room temperature for 24 hrs. 
After pouring the reaction mixture into water, the organic phase was extracted with 
ethyl acetate, the extract washed with diluted solutions of citric acid and sodium 
hydrocarbonate, then with liV ammonium hydroxide and water. The extract was 
dried, evaporated in vacum, and the residue was crystallized. 
p-Nitrobenzyl t-butyloxycarbonyl-glycyl-L-phenylalanyl-L-seryl-D-pipecolyl-
-L-phenylalanyl-L-nitroargininate (5) 
3.79 g (4 mmole) protected pentapeptide ester (3) was treated in slight excess 
of trifluoroacetic acid at room temperature for 1 hour. The excess acid was evaporated 
in vacuum, and the trifluoroacetate of the pentapeptide ester precipitated with ether, 
then filtered, washed with ether and dried in vacuum. The dried product was dis-
solved in 15 ml dimethylformamide, the equivalent quantity of N-methylmorpholine 
was added and the solution cooled to 0°C. Finally 1.18 g (4 mmole) N-hydroxy-
succinimide i-butyloxycarbonyl-glycynate was given to the reaction mixture and 
worked up as. above (4). 
Methyl benzyloxycarbonyl-glycyl-L-phenylalanyl-L-seryl-L-pipecolyl-
. -L-phenylalanyl-L-nitroargininate (7) 
1.87 g (3 mmole) methyl benzyloxycarbonyl-L-pipecolyl-L-phenylalanyl-L-
nitroargininate [14] was dissolved in excess AN hydrogen bromide—acetic acid, 
stirred at 0°C for 45 minutes and the hydrobromide of the tripeptide ester was 
precipitated with ether, filtered, washed with ether and dried in vacuum over P2O5. 
and potassium hydroxide. The dried product was dissolved in 10 ml dimethyl-
formamide, the solution cooled to — 15°C and neutralized with N-methylmorpholine. 
At the same time, 1.37 g (3 mmole) benzyloxycarbonyl-glycyl-L-phenylalanyl-L-
serine hydrazide was dissolved in 6 ml dimethylformamide, the solution cooled 
to — 15°C, then 1.5 ml 6iV. hydrochloric acid and 0.22 g cc. aqueous sodium nitrite 
Table t 










c = 1 
D M F 
Formula 
Analysis, % 
• Calc. Found 
N N 
B0C-Ser -D-Pip-Phe-Arg(N0 2 ) -0Nb (1) A a 57 102—105 - 3 2 ° C „ H 4 B O t , N , 15.7 15.6 
B0C-Ser -P ip-Phe-Arg(N0 2 )0Me (2) A a 64 92—97 - 3 0 ° CsoííáfiOioNg 16.5 16.3 
B0C-Phe-Ser-D-Pip-Phe-Arg(N0 2 ) -
- O N b (3) A a 88 113—116 - 2 0 ° C45H58OI3N10 14.8 14.7 
B0C-Phe-Ser-Pip-Phe-Arg(N0 2)-
- O M e (4) A a 77 95—98 - 3 8 ° CaoHsfiOuNo 15.3 15.3 
B0C-Gly-Phe-Ser-D-Pip-Phe-Arg(N0 2)-
- O N b (5) A b 81 114—118 - 1 8 ° C47H61O14N11 15.4 15.2 
B0C-Gly-Phe-Ser-Pip-Phe-Arg(N02)-
-OMe (6) A b 80 108—113 - 3 3 ° CIIHJJSOIANU 15.9 15.7 
Z-Gly-Phe-Ser-Pip-Phe-Arg(N02)-
- O M e (7) B c 67 163—168 - 3 5 ° C44H60O12N10 15.3 15.2 
Z-Gly-Phe-Ser-Pip-Phe-Arg-(N02)-
- O N b (8) B c 73 164—170 - 3 8 ° Q O H ^ O ^ N , , 14.9 14.8 
BOC-Pro-Gly-Phe-Ser-D-Pip-Phe-
- A r g ( N 0 2 ) - 0 N b (9) A. c 80 122—124 - 3 0 ° C 6 2 H 6 6 O 1 5 N 1 2 







- A r g ( N 0 2 ) - 0 M e (10) A . c 78 121—124 - 4 0 ° C 4 7 H „ , O 1 3 N „ 
Arg. 0.95, 




. - A r g ( N 0 2 ) - 0 N b (11) A d 56 128—132 - 3 1 ° C57H7 50 1 6NJ 3 
Arg 0.96, 
Phe 1.87, 




























1 E tOAc = ethyl acetate, E t O H = ethanol, MeOH = methanol, E t 2 0 = ether, P. E. = petroleum ether 
a A = stepwise condensation, B = fragment condensation 
3 a = EtOAc-P. E., b = E t 0 H / E t 2 0 , c = MeOH/Et a O, d = ace tone/Et 2 0 
* amino-acid analysis was made instead of elemental analysis 
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solution was added drop wise. After further stirring for 5 minutes the azide solution 
was added to the solution of the amino-compohent and the reaction mixture was 
stirred under — 5°C for 3 hrs. After 24 hrs standing in a refrigerator, the solution 
was eveporated in vacuum and the . residue suspended in 1:1 ethyl acetate—water. 
The organic phase was washed with diluted hydrochloric acid, diluted sodium 
carbonate solution and water. After drying and evaporating the ethyl acetate 
solution in vacuum, the residue was crystallized. 
p-Nitrobenzyl t-butyloxycarbonyl-L-prolyl-glycyl-L-phenylalanyl-L-seryl-
-D-pipecolyl-L-phenylalanyl-L-nitroargininate (9) 
2.5 g (2.5 mmole) protected hexapeptide ester (5) was treated in slight excess 
of trifluoroacetic acid at room temperature for 1 hour. The excess acid was evaporated 
in vacuum, the trifluoroacetate of the hexapeptide ester precipitated with ether, 
then filtered and washed with ether. The product was dissolved in 8 ml dimethyl-
formamide, the solution cooled undér 0°C and neutralized with N-methylmorpholine 
added dropwise.. After, adding 0.78 g (2.5 mmole) N-hydroxysuccinimide i-butyl-
oxycarbonyl-L-prolinate the reaction, mixture was worked up as described for 1. 
Methyl t-butyloxycarbonyl-L-prolyl-L-pipecolyl-glycyl-L-phenylalanyl-
-L-seryl-L-pipecolyl-L-phenylalanyl-L-nitroargininate (12) íj 
.0.91 g (1 mmole) protected heptapeptide ester (10) was treated with slight 
excess of trifluoroacetic acid at room temperature for 1 hour. The excess acid was 
evaporated in vacuum, the remaining trifluoroacetate of the heptapeptide ester pre-
cipitated with ether, filtered, washed with ether and dissolved in 5 ml dimethyl-
formamide. The solution was cooled to 0°C and, after adding 0.14 ml triethylamine, 
the precipitated triethylamine hydrochloride was filtered. . 0.12 g (1.0 mmole) 
i-butyloxycarbonyl-L-proline and 0.2 g (10 mmole) dicyclohexylcarbodiimide were 
added to the filtrate and the reaction mixture was stirred at the same temperature 
for 6 hrs, then left to stand in a refrigerator for 24 hrs. After filtering off the dicyclo-
hexylurea, the filtrate was evaporated in vacuum, the residue dissolved in acetone 
and the protected octapeptide ester was crystallized by addition of ether. 
* * * ' 
The authors are indebted to thanks to Mrs. G . B A R T Ó K - B O Z Ó K I and Mrs. 
É . G Á C S - G E R G E L Y for elemental analysis, to R . F E R E N C Z I for amino-acid analysis, 
and to Miss I. B A G I and J. F Ü L Ö P for technical assistance. 
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СИНТЕЗ ФРАГМЕНТОВ АНАЛОГОВ БРАДИКИНИНА, 
СОДЕРЖАЩИХ ОПТИЧЕСКИ АКТИВНУЮ ПИПЕКОЛИНОВУЮ КИСЛОТУ 
Л. Балашпири, Б. Пенке, Дь. Папп, К. Ковач 
Авторами синтетизированы и определены физические константы нескольких пепти-
дов, содержащих «L» и «D» пипеколиновую кислоту, которые соответствуют фрагментам 
аналогов брадикинина с тшеколиновой кислотой. 
